CoChat
Sign Up
Cited by 73Cancer Genomics and DiagnosticsBioinformatics and Genomic NetworksBRCA gene mutations in cancer

Characterization of potential driver mutations involved in human breast cancer by computational approaches

Open access
Rajendran, Barani Kumar, Deng, Chu-Xia·2017·Oncotarget
DOI 10.18632/oncotarget.17225PMC PMC5564847
Open this paper in CoChat — free accountOpen PDF

Abstract

// Barani Kumar Rajendran 1 and Chu-Xia Deng 1 1 Cancer Research Centre, Faculty of Health Sciences, University of Macau, Macau SAR, China Correspondence to: Chu-Xia Deng, email: cxdeng@umac.mo Keywords: driver mutations, breast cancer, cancer drivers, breast cancer driver genes, genetic mutations Received: February 08, 2017 Accepted: March 26, 2017 Published: April 19, 2017 ABSTRACT Breast cancer is the second most frequently occurring form of cancer and is also the second most lethal cancer in women worldwide. A genetic mutation is one of the key factors that alter multiple cellular regulatory pathways and drive breast cancer initiation and progression yet nature of these cancer drivers remains elusive. In this article, we have reviewed various computational perspectives and algorithms for exploring breast cancer driver mutation genes. Using both frequency based and mutational exclusivity based approaches, we identified 195 driver genes and shortlisted 63 of them as candidate drivers for breast cancer using various computational approaches. Finally, we conducted network and pathway analysis to explore their functions in breast tumorigenesis including tumor initiation, progression, and metastasis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.17225

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In human tumors, altered expression of endocytic regulatory factors such as clathrin-hc, clathrin-like, Caveolin-1, Nexin-1, and Numb along with driver mutations are crucial for endocytosis.

    “In addition, in human tumors, altered expression of various endocytic regulatory factors such as clathrin-hc, clathrin- like, Caveolin-1, Nexin-1, and Numb along with driver mutations are crucial for endocytosis [102,103].”

    From Insights of Endocytosis Signaling in Health and Disease (2023) · cites this paper as [102]

    The Introduction and ‘Functional Effects of Breast Cancer Drivers in Tumorigenesis’ discuss driver mutations and their roles in cancer, but do not connect them to endocytosis. Searches for endocytosis, clathrin, Caveolin-1, Nexin-1, and Numb found no passage addressing the claimed altered expression of those factors or their role in endocytosis. The supplied passages have no page numbers. (LLM, conf=0.72)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 163

  1. [1]Ferlay J Soerjomataram I Dikshit R Eser S Mathers C Rebelo M Parkin DM Forman D Bray F Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 Int J Cancer 2015 136 E359 86 25220842
  2. [2]Siegel RL Miller KD Jemal A Cancer statistics, 2016 CA Cancer J Clin 2016 66 7 30 26742998
  3. [3]Xu X Qiao W Linke SP Cao L Li WM Furth PA Harris CC Deng CX Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis Nat Genet 2001 28 266 71 11431698
  4. [4]Osborne C Wilson P Tripathy D Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications Oncologist 2004 9 361 77 15266090
  5. [5]Burke W Petersen G Lynch P Botkin J Daly M Garber J Kahn MJ McTiernan A Offit K Thomson E Varricchio C Cancer Genetics Studies Consortium Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer JAMA 1997 277 915 19 9062331
  6. [6]Kerangueven F Essioux L Dib A Noguchi T Allione F Geneix J Longy M Lidereau R Eisinger F Pébusque MJ Jacquemeir J Bonaiti-Pellie C Sobol H Birnbaum D Loss of heterozygosity and linkage analysis in breast carcinoma: indication for a putative third susceptibility gene on the short arm of chromosome 8 Oncogene 1995 10 1023 26 7898921
  7. [7]Kılıç Y Çelebiler AC Sakızlı M Selecting housekeeping genes as references for the normalization of quantitative PCR data in breast cancer Clin Transl Oncol 2014 16 184 90 23720140
  8. [8]Vogelstein B Papadopoulos N Velculescu VE Zhou S Diaz LA Jr Kinzler KW Cancer genome landscapes Science 2013 339 1546 58 23539594 PMC3749880
  9. [9]Kalari S Pfeifer GP Identification of driver and passenger DNA methylation in cancer by epigenomic analysis Adv Genet 2010 70 277 308 20920752 PMC2951285
  10. [11]Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours Nature 2012 490 61 70 23000897 PMC3465532
  11. [12]Stratton MR Campbell PJ Futreal PA The cancer genome Nature 2009 458 719 24 19360079 PMC2821689
  12. [13]Turnbull C Rahman N Genetic predisposition to breast cancer: past, present, and future Annu Rev Genomics Hum Genet 2008 9 321 45 18544032
  13. [14]Takaku M Grimm SA Wade PA Gata3 in breast cancer: tumor suppressor or oncogene? Gene Expr 2015 16 163 68 26637396 PMC4758516
  14. [15]Wood LD Parsons DW Jones S Lin J Sjöblom T Leary RJ Shen D Boca SM Barber T Ptak J Silliman N Szabo S Dezso Z The genomic landscapes of human breast and colorectal cancers Science 2007 318 1108 13 17932254
  15. [16]Kan Z Jaiswal BS Stinson J Janakiraman V Bhatt D Stern HM Yue P Haverty PM Bourgon R Zheng J Moorhead M Chaudhuri S Tomsho LP Diverse somatic mutation patterns and pathway alterations in human cancers Nature 2010 466 869 73 20668451
  16. [18]Sjöblom T Jones S Wood LD Parsons DW Lin J Barber TD Mandelker D Leary RJ Ptak J Silliman N Szabo S Buckhaults P Farrell C The consensus coding sequences of human breast and colorectal cancers Science 2006 314 268 74 16959974
  17. [19]Banerji S Cibulskis K Rangel-Escareno C Brown KK Carter SL Frederick AM Lawrence MS Sivachenko AY Sougnez C Zou L Cortes ML Fernandez-Lopez JC Peng S Sequence analysis of mutations and translocations across breast cancer subtypes Nature 2012 486 405 09 22722202 PMC4148686
  18. [20]Petrij-Bosch A Peelen T van Vliet M van Eijk R Olmer R Drüsedau M Hogervorst FB Hageman S Arts PJ Ligtenberg MJ Meijers-Heijboer H Klijn JG Vasen HF BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients Nat Genet 1997 17 341 45 9354803
  19. [21]Birgisdottir V Stefansson OA Bodvarsdottir SK Hilmarsdottir H Jonasson JG Eyfjord JE Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer Breast Cancer Res 2006 8 R38 16846527 PMC1779478
  20. [22]Gabai-Kapara E Lahad A Kaufman B Friedman E Segev S Renbaum P Beeri R Gal M Grinshpun-Cohen J Djemal K Mandell JB Lee MK Beller U Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2 Proc Natl Acad Sci USA 2014 111 14205 10 25192939 PMC4191771
  21. [23]Campeau PM Foulkes WD Tischkowitz MD Hereditary breast cancer: new genetic developments, new therapeutic avenues Hum Genet 2008 124 31 42 18575892
  22. [24]Nelen MR Padberg GW Peeters EA Lin AY van den Helm B Frants RR Coulon V Goldstein AM van Reen MM Easton DF Eeles RA Hodgsen S Mulvihill JJ Localization of the gene for Cowden disease to chromosome 10q22-23 Nat Genet 1996 13 114 16 8673088
  23. [25]Hemminki A Tomlinson I Markie D Järvinen H Sistonen P Björkqvist AM Knuutila S Salovaara R Bodmer W Shibata D de la Chapelle A Aaltonen LA Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis Nat Genet 1997 15 87 90 8988175
  24. [26]Pharoah PD Guilford P Caldas C International Gastric Cancer Linkage Consortium Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families Gastroenterology 2001 121 1348 53 11729114
  25. [27]Easton DF Ford D Bishop DT Breast Cancer Linkage Consortium Breast and ovarian cancer incidence in BRCA1-mutation carriers Am J Hum Genet 1995 56 265 71 7825587 PMC1801337
  26. [28]Ford D Easton DF Stratton M Narod S Goldgar D Devilee P Bishop DT Weber B Lenoir G Chang-Claude J Sobol H Teare MD Struewing J Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families Am J Hum Genet 1998 62 676 89 9497246 PMC1376944
  27. [30]Chen S Parmigiani G Meta-analysis of BRCA1 and BRCA2 penetrance J Clin Oncol 2007 25 1329 33 17416853 PMC2267287
  28. [31]Ashworth A Lord CJ Reis-Filho JS Genetic interactions in cancer progression and treatment Cell 2011 145 30 38 21458666
  29. [32]Cremona CA Behrens A ATM signalling and cancer Oncogene 2014 33 3351 60 23851492
  30. [33]Masson AL Talseth-Palmer BA Evans TJ Grice DM Hannan GN Scott RJ Expanding the genetic basis of copy number variation in familial breast cancer Hered Cancer Clin Pract 2014 12 15 24955146 PMC4064283
  31. [34]Seal S Thompson D Renwick A Elliott A Kelly P Barfoot R Chagtai T Jayatilake H Ahmed M Spanova K North B McGuffog L Evans DG Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles Nat Genet 2006 38 1239 41 17033622
  32. [35]Buslov KG Iyevleva AG Chekmariova EV Suspitsin EN Togo AV Kuligina ES Sokolenko AP Matsko DE Turkevich EA Lazareva YR Chagunava OL Bit-Sava EM Semiglazov VF NBS1 657del5 mutation may contribute only to a limited fraction of breast cancer cases in Russia Int J Cancer 2005 114 585 89 15578693
  33. [37]Nusbaum R Vogel KJ Ready K Susceptibility to breast cancer: hereditary syndromes and low penetrance genes Breast Dis 2006-2007 27 21 50 17917139
  34. [38]Rouleau E Jesson B Briaux A Nogues C Chabaud V Demange L Sokolowska J Coulet F Barouk-Simonet E Bignon YJ Bonnet F Bourdon V Bronner M Rare germline large rearrangements in the BRCA1/2 genes and eight candidate genes in 472 patients with breast cancer predisposition Breast Cancer Res Treat 2012 133 1179 90 22476849
  35. [39]Sommer SS Jiang Z Feng J Buzin CH Zheng J Longmate J Jung M Moulds J Dritschilo A ATM missense mutations are frequent in patients with breast cancer Cancer Genet Cytogenet 2003 145 115 20 12935922
  36. [40]Katagiri T Kasumi F Yoshimoto M Nomizu T Asaishi K Abe R Tsuchiya A Sugano M Takai S Yoneda M Fukutomi T Nanba K Makita M High proportion of missense mutations of the BRCA1 and BRCA2 genes in Japanese breast cancer families J Hum Genet 1998 43 42 48 9609997
  37. [41]Vallon-Christersson J Cayanan C Haraldsson K Loman N Bergthorsson JT Brøndum-Nielsen K Gerdes AM Møller P Kristoffersson U Olsson H Borg A Monteiro AN Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families Hum Mol Genet 2001 10 353 60 11157798 PMC4756649
  38. [42]Malkin D Li FP Strong LC Fraumeni JF Jr Nelson CE Kim DH Kassel J Gryka MA Bischoff FZ Tainsky MA Friend SH Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms Science 1990 250 1233 38 1978757
  39. [43]Gasco M Shami S Crook T The p53 pathway in breast cancer Breast Cancer Res 2002 4 70 76 11879567 PMC138723
  40. [44]Giacomazzi J Selistre SG Rossi C Alemar B Santos-Silva P Pereira FS Netto CB Cossio SL Roth DE Brunetto AL Zagonel-Oliveira M Martel-Planche G Goldim JR Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil Cancer 2013 119 4341 49 24122735
  41. [45]Kouidou S Malousi A Maglaveras N Li-Fraumeni and Li-Fraumeni-like syndrome mutations in p53 are associated with exonic methylation and splicing regulatory elements Mol Carcinog 2009 48 895 902 19367569
  42. [46]Borges LM Ayres FM R337H mutation of the TP53 gene as a clinical marker in cancer patients: a systematic review of literature Genet Mol Res 2015 14 17034 43 26681051
  43. [47]Yang X Hu Z Wu J Liu G Di G Chen C Hou Y Huang X Liu Z Shen Z Shao Z [Germline mutations of TP53 gene among Chinese families with high risk for breast cancer] [Article in Chinese] Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2015 32 761 65 26663043
  44. [48]Macedo GS Araujo Vieira I Brandalize AP Giacomazzi J Inez Palmero E Volc S Rodrigues Paixão-Côrtes V Caleffi M Silva Alves M Achatz MI Hainaut P Ashton-Prolla P Rare germline variant (rs78378222) in the TP53 3′ UTR: evidence for a new mechanism of cancer predisposition in Li-Fraumeni syndrome Cancer Genet 2016 209 97 106 26823150
  45. [49]Torkamani A Schork NJ Identification of rare cancer driver mutations by network reconstruction Genome Res 2009 19 1570 78 19574499 PMC2752121
  46. [50]Shlien A Malkin D Copy number variations and cancer Genome Med 2009 1 62 19566914 PMC2703871
  47. [51]Stephens PJ Tarpey PS Davies H Van Loo P Greenman C Wedge DC Nik-Zainal S Martin S Varela I Bignell GR Yates LR Papaemmanuil E Beare D The landscape of cancer genes and mutational processes in breast cancer Nature 2012 486 400 04 22722201 PMC3428862
  48. [52]Pereira B Chin SF Rueda OM Vollan HK Provenzano E Bardwell HA Pugh M Jones L Russell R Sammut SJ Tsui DW Liu B Dawson SJ The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes Nat Commun 2016 7 11479 27161491 PMC4866047
  49. [53]Tokheim CJ Papadopoulos N Kinzler KW Vogelstein B Karchin R Evaluating the evaluation of cancer driver genes Proc Natl Acad Sci USA 2016 113 14330 35 27911828 PMC5167163
  50. [54]Greenman C Stephens P Smith R Dalgliesh GL Hunter C Bignell G Davies H Teague J Butler A Stevens C Edkins S O'Meara S Vastrik I Patterns of somatic mutation in human cancer genomes Nature 2007 446 153 58 17344846 PMC2712719
  51. [55]Haber DA Settleman J Cancer: drivers and passengers Nature 2007 446 145 46 17344839
  52. [56]De Carvalho DD Sharma S You JS Su SF Taberlay PC Kelly TK Yang X Liang G Jones PA DNA methylation screening identifies driver epigenetic events of cancer cell survival Cancer Cell 2012 21 655 67 22624715 PMC3395886
  53. [57]Liu Y Hu Z Identification of collaborative driver pathways in breast cancer BMC Genomics 2014 15 605 25034939 PMC4111852
  54. [58]Szabo A Boucher K Estimating an oncogenetic tree when false negatives and positives are present Math Biosci 2002 176 219 36 11916510
  55. [59]Gao J Aksoy BA Dogrusoz U Dresdner G Gross B Sumer SO Sun Y Jacobsen A Sinha R Larsson E Cerami E Sander C Schultz N Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal Sci Signal 2013 6 l1 PMC4160307 23550210
  56. [60]Forbes SA Tang G Bindal N Bamford S Dawson E Cole C Kok CY Jia M Ewing R Menzies A Teague JW Stratton MR Futreal PA COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer Nucleic Acids Res 2010 38 D652 57 19906727 PMC2808858
  57. [61]Abecasis GR Altshuler D Auton A Brooks LD Durbin RM Gibbs RA Hurles ME McVean GA 1000 Genomes Project Consortium A map of human genome variation from population-scale sequencing Nature 2010 467 1061 73 20981092 PMC3042601
  58. [62]Gonzalez-Perez A Perez-Llamas C Deu-Pons J Tamborero D Schroeder MP Jene-Sanz A Santos A Lopez-Bigas N IntOGen-mutations identifies cancer drivers across tumor types Nat Methods 2013 10 1081 82 24037244 PMC5758042
  59. [63]Cheng WC Chung IF Chen CY Sun HJ Fen JJ Tang WC Chang TY Wong TT Wang HW DriverDB: an exome sequencing database for cancer driver gene identification Nucleic Acids Res 2014 42 D1048 54 24214964 PMC3965046
  60. [64]Chen Y Hao J Jiang W He T Zhang X Jiang T Jiang R Identifying potential cancer driver genes by genomic data integration Sci Rep 2013 3 3538 24346768 PMC3866686
  61. [65]Tamborero D Gonzalez-Perez A Perez-Llamas C Deu-Pons J Kandoth C Reimand J Lawrence MS Getz G Bader GD Ding L Lopez-Bigas N Comprehensive identification of mutational cancer driver genes across 12 tumor types Sci Rep 2013 3 2650 24084849 PMC3788361
  62. [66]Sim NL Kumar P Hu J Henikoff S Schneider G Ng PC SIFT web server: predicting effects of amino acid substitutions on proteins Nucleic Acids Res 2012 40 W452 7 22689647 PMC3394338
  63. [67]Adzhubei IA Schmidt S Peshkin L Ramensky VE Gerasimova A Bork P Kondrashov AS Sunyaev SR A method and server for predicting damaging missense mutations Nat Methods 2010 7 248 49 20354512 PMC2855889
  64. [68]Reva B Antipin Y Sander C Predicting the functional impact of protein mutations: application to cancer genomics Nucleic Acids Res 2011 39 e118 21727090 PMC3177186
  65. [69]Chung IF Chen CY Su SC Li CY Wu KJ Wang HW Cheng WC DriverDBv2: a database for human cancer driver gene research Nucleic Acids Res 2016 44 D975 79 26635391 PMC4702919
  66. [70]Reimand J Bader GD Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers Mol Syst Biol 2013 9 637 23340843 PMC3564258
  67. [71]Vandin F Upfal E Raphael BJ De novo discovery of mutated driver pathways in cancer Genome Res 2012 22 375 85 21653252 PMC3266044
  68. [72]Leiserson MD Blokh D Sharan R Raphael BJ Simultaneous identification of multiple driver pathways in cancer PLOS Comput Biol 2013 9 e1003054 23717195 PMC3662702
  69. [73]Zhao J Zhang S Wu LY Zhang XS Efficient methods for identifying mutated driver pathways in cancer Bioinformatics 2012 28 2940 47 22982574
  70. [74]Youn A Simon R Identifying cancer driver genes in tumor genome sequencing studies Bioinformatics 2011 27 175 81 21169372 PMC3018819
  71. [75]Cerami E Demir E Schultz N Taylor BS Sander C Automated network analysis identifies core pathways in glioblastoma PLoS One 2010 5 e8918 20169195 PMC2820542
  72. [76]Lawrence MS Stojanov P Polak P Kryukov GV Cibulskis K Sivachenko A Carter SL Stewart C Mermel CH Roberts SA Kiezun A Hammerman PS McKenna A Mutational heterogeneity in cancer and the search for new cancer-associated genes Nature 2013 499 214 18 23770567 PMC3919509
  73. [77]Ciriello G Cerami E Sander C Schultz N Mutual exclusivity analysis identifies oncogenic network modules Genome Res 2012 22 398 406 21908773 PMC3266046
  74. [78]Porta-Pardo E Godzik A e-Driver: a novel method to identify protein regions driving cancer Bioinformatics 2014 30 3109 14 25064568 PMC4609017
  75. [79]Hou JP Ma J DawnRank: discovering personalized driver genes in cancer Genome Med 2014 6 56 25177370 PMC4148527
  76. [80]Bashashati A Haffari G Ding J Ha G Lui K Rosner J Huntsman DG Caldas C Aparicio SA Shah SP DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer Genome Biol 2012 13 R124 23383675 PMC4056374
  77. [81]Jia P Wang Q Chen Q Hutchinson KE Pao W Zhao Z MSEA: detection and quantification of mutation hotspots through mutation set enrichment analysis Genome Biol 2014 15 489 25348067 PMC4226881
  78. [82]Ryslik GA Cheng Y Cheung KH Modis Y Zhao H Utilizing protein structure to identify non-random somatic mutations BMC Bioinformatics 2013 14 190 23758891 PMC3691676
  79. [83]Zhang J Wu LY Zhang XS Zhang S Discovery of co-occurring driver pathways in cancer BMC Bioinformatics 2014 15 271 25106096 PMC4133618
  80. [84]Greenman C Wooster R Futreal PA Stratton MR Easton DF Statistical analysis of pathogenicity of somatic mutations in cancer Genetics 2006 173 2187 98 16783027 PMC1569711
  81. [85]Schmitt T Ogris C Sonnhammer EL FunCoup 3.0: database of genome-wide functional coupling networks Nucleic Acids Res 2014 42 D380 88 24185702 PMC3965084
  82. [86]Warde-Farley D Donaldson SL Comes O Zuberi K Badrawi R Chao P Franz M Grouios C Kazi F Lopes CT Maitland A Mostafavi S Montojo J The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function Nucleic Acids Res 2010 38 W214 20 20576703 PMC2896186
  83. [87]Benito-Martin A Peinado H FunRich proteomics software analysis, let the fun begin! Proteomics 2015 15 2555 56 26149235
  84. [88]Carter H Chen S Isik L Tyekucheva S Velculescu VE Kinzler KW Vogelstein B Karchin R Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations Cancer Res 2009 69 6660 67 19654296 PMC2763410
  85. [89]Vaser R Adusumalli S Leng SN Sikic M Ng PC SIFT missense predictions for genomes Nat Protoc 2016 11 1 9 26633127
  86. [90]Pon JR Marra MA Driver and passenger mutations in cancer Annu Rev Pathol 2015 10 25 50 25340638
  87. [92]Tan H Bao J Zhou X Genome-wide mutational spectra analysis reveals significant cancer-specific heterogeneity Sci Rep 2015 5 12566 26212640 PMC4515826
  88. [93]Azim HA Jr Nguyen B Brohée S Zoppoli G Sotiriou C Genomic aberrations in young and elderly breast cancer patients BMC Med 2015 13 266 26467651 PMC4606505
  89. [94]Skaaby T Husemoen LL Thyssen JP Meldgaard M Thuesen BH Pisinger C Jørgensen T Carlsen K Johansen JD Menné T Szecsi PB Stender S Linneberg A Filaggrin loss-of-function mutations and incident cancer: a population-based study Br J Dermatol 2014 171 1407 14 24628370
  90. [95]Shriver M Stroka KM Vitolo MI Martin S Huso DL Konstantopoulos K Kontrogianni-Konstantopoulos A Loss of giant obscurins from breast epithelium promotes epithelial-to-mesenchymal transition, tumorigenicity and metastasis Oncogene 2015 34 4248 59 25381817 PMC4426246
  91. [96]Perry NA Shriver M Mameza MG Grabias B Balzer E Kontrogianni-Konstantopoulos A Loss of giant obscurins promotes breast epithelial cell survival through apoptotic resistance FASEB J 2012 26 2764 75 22441987 PMC4046098
  92. [97]Cornen S Guille A Adélaïde L Addou-Klouche J Finetti P Saade MR Manai M Carbuccia N Bekhouche I Letessier A Raynaud S Charafe-Jauffret E Jacquemier J Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profiling PLoS One 2014 9 e81843 24416132 PMC3886975
  93. [98]Zhao H Wang J Han Y Huang Z Ying J Bi X Zhao J Fang Y Zhou H Zhou J Li Z Zhang Y Yang X ARID2: a new tumor suppressor gene in hepatocellular carcinoma Oncotarget 2011 2 886 91 10.18632/oncotarget.355 22095441 PMC3259997 · DOI
  94. [99]Aso T Uozaki H Morita S Kumagai A Watanabe M Loss of arid1a, arid1b, and arid2 expression during progression of gastric cancer Anticancer Res 2015 35 6819 27 26637902
  95. [100]Hong SH Goh SH Lee SJ Hwang JA Lee J Choi IJ Seo H Park JH Suzuki H Yamamoto E Kim IH Jeong JS Ju MH Upregulation of adenylate cyclase 3 (ADCY3) increases the tumorigenic potential of cells by activating the CREB pathway Oncotarget 2013 4 1791 803 10.18632/oncotarget.1324 24113161 PMC3858564 · DOI
  96. [101]Son HS Shin YM Park KK Seo KW Yoon KY Jang HK Lee SH Yang SI Kim JH Correlation between her2 overexpression and clinicopathological characteristics in gastric cancer patients who have undergone curative resection J Gastric Cancer 2014 14 180 86 25328763 PMC4199885
  97. [102]Ouyang Q Tian C Gao J Huang J Fu H He J Yang J HER2-positive double primary tumor of gastric and breast cancer occur synchronously in a patient: A case report Mol Clin Oncol 2016 4 719 22 27123269 PMC4840576
  98. [103]Zhao J Xu H He M Wang Z Wu Y Rho gtpase-activating protein 35 rs1052667 polymorphism and osteosarcoma risk and prognosis Biomed Res Int 2014 2014 396947 25136583 PMC4124850
  99. [104]Wolf RM Draghi N Liang X Dai C Uhrbom L Eklöf C Westermark B Holland EC Resh MD p190RhoGAP can act to inhibit PDGF-induced gliomas in mice: a putative tumor suppressor encoded on human chromosome 19q13.3 Genes Dev 2003 17 476 87 12600941 PMC196001
  100. [105]Manceau G Letouzé E Guichard C Didelot A Cazes A Corté H Fabre E Pallier K Imbeaud S Le Pimpec-Barthes F Zucman-Rossi J Laurent-Puig P Blons H Recurrent inactivating mutations of ARID2 in non-small cell lung carcinoma Int J Cancer 2013 132 2217 21 23047306
  101. [106]Dunn GP Cheung HW Agarwalla PK Thomas S Zektser Y Karst AM Boehm JS Weir BA Berlin AM Zou L Getz G Liu JF Hirsch M In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene Proc Natl Acad Sci USA 2014 111 1102 07 24385586 PMC3903232
  102. [107]Fujimoto A Furuta M Totoki Y Tsunoda T Kato M Shiraishi Y Tanaka H Taniguchi H Kawakami Y Ueno M Gotoh K Ariizumi S Wardell CP Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer Nat Genet 2016 48 500 09 27064257
  103. [108]Zhu L Li Q Wong SH Huang M Klein BJ Shen J Ikenouye L Onishi M Schneidawind D Buechele C Hansen L Duque-Afonso J Zhu F Ash1l links histone h3 lysine 36 dimethylation to mll leukemia Cancer Discov 2016 6 770 83 27154821 PMC4930721
  104. [109]Liu L Kimball S Liu H Holowatyj A Yang ZQ Genetic alterations of histone lysine methyltransferases and their significance in breast cancer Oncotarget 2015 6 2466 82 10.18632/oncotarget.2967 25537518 PMC4385864 · DOI
  105. [110]Zhong BL Bian LJ Wang GM Zhou YF Chen YY Peng F Identification of key genes involved in HER2-positive breast cancer Eur Rev Med Pharmacol Sci 2016 20 664 72 26957268
  106. [111]Xu L Li X Chu ES Zhao G Go MY Tao Q Jin H Zeng Z Sung JJ Yu J Epigenetic inactivation of BCL6B, a novel functional tumour suppressor for gastric cancer, is associated with poor survival Gut 2012 61 977 85 21917650
  107. [112]Crippa E Folini M Pennati M Zaffaroni N Pierotti MA Gariboldi M miR-342 overexpression results in a synthetic lethal phenotype in BRCA1-mutant HCC1937 breast cancer cells Oncotarget 2016 7 18594 604 10.18632/oncotarget.7617 26919240 PMC4951312 · DOI
  108. [113]Wang CY Lai MD Phan NN Sun Z Lin YC Meta-analysis of public microarray datasets reveals voltage-gated calcium gene signatures in clinical cancer patients PLoS One 2015 10 e0125766 26147197 PMC4493072
  109. [114]Yu W Wang P Ma H Zhang G Yulin Z Lu B Wang H Dong M Suppression of T-type Ca2+ channels inhibited human laryngeal squamous cell carcinoma cell proliferation running title: roles of T-type Ca2+ channels in LSCC cell proliferation Clin Lab 2014 60 621 28 24779296
  110. [115]Buchanan PJ McCloskey KD CaV channels and cancer: canonical functions indicate benefits of repurposed drugs as cancer therapeutics Eur Biophys J 2016 45 621 33 27342111 PMC5045480
  111. [116]Petitclerc E Boutaud A Prestayko A Xu J Sado Y Ninomiya Y Sarras MP Jr Hudson BG Brooks PC New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo J Biol Chem 2000 275 8051 61 10713126
  112. [117]Kuo DS Labelle-Dumais C Gould DB COL4A1 and COL4A2 mutations and disease: insights into pathogenic mechanisms and potential therapeutic targets Hum Mol Genet 2012 21 R97 110 22914737 PMC3459649
  113. [118]Wu Y Shin-ya K Brosh RM Jr FANCJ helicase defective in Fanconia anemia and breast cancer unwinds G-quadruplex DNA to defend genomic stability Mol Cell Biol 2008 28 4116 28 18426915 PMC2423121
  114. [119]Tao S Wang Z Feng J Hsu FC Jin G Kim ST Zhang Z Gronberg H Zheng LS Isaacs WB Xu J Sun J A genome-wide search for loci interacting with known prostate cancer risk-associated genetic variants Carcinogenesis 2012 33 598 603 22219177 PMC3291863
  115. [120]Braun R Finney R Yan C Chen QR Hu Y Edmonson M Meerzaman D Buetow K Discovery analysis of TCGA data reveals association between germline genotype and survival in ovarian cancer patients PLoS One 2013 8 e55037 23555554 PMC3605427
  116. [121]Joshi R Tawfik A Edeh N McCloud V Looney S Lewis J Hsu S Ogbureke KU Dentin sialophosphoprotein (DSPP) gene-silencing inhibits key tumorigenic activities in human oral cancer cell line, OSC2 PLoS One 2010 5 e13974 21103065 PMC2980487
  117. [122]Jain A McKnight DA Fisher LW Humphreys EB Mangold LA Partin AW Fedarko NS Small integrin-binding proteins as serum markers for prostate cancer detection Clin Cancer Res 2009 15 5199 207 19671866 PMC2766346
  118. [123]Bandaru S Zhou AX Rouhi P Zhang Y Bergo MO Cao Y Akyürek LM Targeting filamin B induces tumor growth and metastasis via enhanced activity of matrix metalloproteinase-9 and secretion of VEGF-A Oncogenesis 2014 3 e119 25244493 PMC4183982
  119. [124]Shapiro IM Cheng AW Flytzanis NC Balsamo M Condeelis JS Oktay MH Burge CB Gertler FB An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype PLoS Genet 2011 7 e1002218 21876675 PMC3158048
  120. [125]Fan Y Li D Qian J Liu Y Feng H Li D Increased expression of FERM domain-containing 4A protein is closely associated with the development of rectal cancer Exp Ther Med 2016 11 421 26 26893625 PMC4734186
  121. [126]Moleirinho S Tilston-Lunel A Angus L Gunn-Moore F Reynolds PA The expanding family of FERM proteins Biochem J 2013 452 183 93 23662806
  122. [127]Darcy DG Chiaroni-Clarke R Murphy JM Honeyman JN Bhanot U LaQuaglia MP Simon SM The genomic landscape of fibrolamellar hepatocellular carcinoma: whole genome sequencing of ten patients Oncotarget 2015 6 755 70 10.18632/oncotarget.2712 25605237 PMC4359253 · DOI
  123. [128]Artuso R Papa FT Grillo E Mucciolo M Yasui DH Dunaway KW Disciglio V Mencarelli MA Pollazzon M Zappella M Hayek G Mari F Renieri A Investigation of modifier genes within copy number variations in Rett syndrome J Hum Genet 2011 56 508 15 21593744 PMC3145144
  124. [129]Ripka S Riedel J Neesse A Griesmann H Buchholz M Ellenrieder V Moeller F Barth P Gress TM Michl P Glutamate receptor GRIA3—target of CUX1 and mediator of tumor progression in pancreatic cancer Neoplasia 2010 12 659 67 20689760 PMC2915410
  125. [130]Hamed M Spaniol C Zapp A Helms V Integrative network-based approach identifies key genetic elements in breast invasive carcinoma BMC Genomics 2015 16 S2 PMC4460623 26040466
  126. [131]Cha S Park AY Kang C A genome-wide association study uncovers a genetic locus associated with thoracic-to-hip ratio in koreans PLoS One 2015 10 e0145220 26675016 PMC4686062
  127. [132]Piccinni SA Bolcato-Bellemin AL Klein A Yang VW Kedinger M Simon-Assmann P Lefebvre O Kruppel-like factors regulate the Lama1 gene encoding the laminin alpha1 chain J Biol Chem 2004 279 9103 14 14634001 PMC2225534
  128. [133]Robinson DR Kalyana-Sundaram S Wu YM Shankar S Cao X Ateeq B Asangani IA Iyer M Maher CA Grasso CS Lonigro RJ Quist M Siddiqui J Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer Nat Med 2011 17 1646 51 22101766 PMC3233654
  129. [134]Melchor L Saucedo-Cuevas LP Muñoz-Repeto I Rodríguez-Pinilla SM Honrado E Campoverde A Palacios J Nathanson KL García MJ Benítez J Comprehensive characterization of the DNA amplification at 13q34 in human breast cancer reveals TFDP1 and CUL4A as likely candidate target genes Breast Cancer Res 2009 11 R86 19995430 PMC2815550
  130. [135]Clocchiatti A Di Giorgio E Ingrao S Meyer-Almes FJ Tripodo C Brancolini C Class IIa HDACs repressive activities on MEF2-depedent transcription are associated with poor prognosis of ER+ breast tumors FASEB J 2013 27 942 54 23159930
  131. [136]Zhao M New L Kravchenko VV Kato Y Gram H di Padova F Olson EN Ulevitch RJ Han J Regulation of the MEF2 family of transcription factors by p38 Mol Cell Biol 1999 19 21 30 9858528 PMC83862
  132. [137]Vandepoele K Van Roy N Staes K Speleman F van Roy F A novel gene family NBPF: intricate structure generated by gene duplications during primate evolution Mol Biol Evol 2005 22 2265 74 16079250
  133. [138]Petroziello J Yamane A Westendorf L Thompson M McDonagh C Cerveny C Law CL Wahl A Carter P Suppression subtractive hybridization and expression profiling identifies a unique set of genes overexpressed in non-small-cell lung cancer Oncogene 2004 23 7734 45 15334068
  134. [139]Ulazzi L Sabbioni S Miotto E Veronese A Angusti A Gafà R Manfredini S Farinati F Sasaki T Lanza G Negrini M Nidogen 1 and 2 gene promoters are aberrantly methylated in human gastrointestinal cancer Mol Cancer 2007 6 17 17328794 PMC1831485
  135. [140]Martino-Echarri E Fernández-Rodríguez R Rodríguez-Baena FJ Barrientos-Durán A Torres-Collado AX Plaza-Calonge MC Amador-Cubero S Cortés J Reynolds LE Hodivala-Dilke KM Rodríguez-Manzaneque JC Contribution of ADAMTS1 as a tumor suppressor gene in human breast carcinoma. Linking its tumor inhibitory properties to its proteolytic activity on nidogen-1 and nidogen-2 Int J Cancer 2013 133 2315 24 23681936
  136. [141]Pujuguet P Simian M Liaw J Timpl R Werb Z Bissell MJ Nidogen-1 regulates laminin-1-dependent mammary-specific gene expression J Cell Sci 2000 113 849 58 10671374 PMC2933215
  137. [142]Yanagawa T Denda K Inatani T Fukushima T Tanaka T Kumaki N Inagaki Y Komada M Deficiency of x-linked protein kinase nrk during pregnancy triggers breast tumor in mice Am J Pathol 2016 186 2751 60 27634343
  138. [143]Ford-Speelman DL Roche JA Bowman AL Bloch RJ The rho-guanine nucleotide exchange factor domain of obscurin activates rhoA signaling in skeletal muscle Mol Biol Cell 2009 20 3905 17 19605563 PMC2735489
  139. [144]Braconi C Valeri N Kogure T Gasparini P Huang N Nuovo GJ Terracciano L Croce CM Patel T Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma Proc Natl Acad Sci USA 2011 108 786 91 21187392 PMC3021052
  140. [145]Berx G van Roy F Involvement of members of the cadherin superfamily in cancer Cold Spring Harb Perspect Biol 2009 1 a003129 20457567 PMC2882122
  141. [146]Chen MW Vacherot F De La Taille A Gil-Diez-De-Medina S Shen R Friedman RA Burchardt M Chopin DK Buttyan R The emergence of protocadherin-PC expression during the acquisition of apoptosis-resistance by prostate cancer cells Oncogene 2002 21 7861 71 12420223
  142. [147]Lancaster JM Berchuck A Carney ME Wiseman R Taylor JA Progesterone receptor gene polymorphism and risk for breast and ovarian cancer Br J Cancer 1998 78 277 PMC2062885 9683307
  143. [148]Smith RA Lea RA Curran JE Weinstein SR Griffiths LR Expression of glucocorticoid and progesterone nuclear receptor genes in archival breast cancer tissue Breast Cancer Res 2003 5 R9 12 12559052 PMC154135
  144. [149]Miller TW Rexer BN Garrett JT Arteaga CL Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer Breast Cancer Res 2011 13 224 22114931 PMC3315683
  145. [150]Kok K Geering B Vanhaesebroeck B Regulation of phosphoinositide 3-kinase expression in health and disease Trends Biochem Sci 2009 34 115 27 19299143
  146. [151]Kok K Nock GE Verrall EA Mitchell MP Hommes DW Peppelenbosch MP Vanhaesebroeck B Regulation of p110delta PI 3-kinase gene expression PLoS One 2009 4 e5145 19357769 PMC2663053
  147. [152]Cizkova M Vacher S Meseure D Trassard M Susini A Mlcuchova D Callens C Rouleau E Spyratos F Lidereau R Bièche I PIK3R1 underexpression is an independent prognostic marker in breast cancer BMC Cancer 2013 13 545 24229379 PMC4225603
  148. [153]Morgan-Fisher M Wewer UM Yoneda A Regulation of ROCK activity in cancer J Histochem Cytochem 2013 61 185 98 23204112 PMC3636696
  149. [154]Forbes SA Bhamra G Bamford S Dawson E Kok C Clements J Menzies A Teague JW Futreal PA Stratton MR The catalogue of somatic mutations in cancer (cosmic) Curr Protoc Hum Genet 2008 Chapter 10: Unit 10.11 PMC2705836 18428421
  150. [155]Lochhead PA Wickman G Mezna M Olson MF Activating ROCK1 somatic mutations in human cancer Oncogene 2010 29 2591 98 20140017
  151. [156]Van den Eynden J Fierro AC Verbeke LP Marchal K SomInaClust: detection of cancer genes based on somatic mutation patterns of inactivation and clustering BMC Bioinformatics 2015 16 125 25903787 PMC4410004
  152. [157]Cazier JB Rao SR McLean CM Walker AK Wright BJ Jaeger EE Kartsonaki C Marsden L Yau C Camps C Kaisaki P Taylor J Catto JW Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden Nat Commun 2014 5 3756 24777035 PMC4010643
  153. [158]Seo JS Ju YS Lee WC Shin JY Lee JK Bleazard T Lee J Jung YJ Kim JO Shin JY Yu SB Kim J Lee ER The transcriptional landscape and mutational profile of lung adenocarcinoma Genome Res 2012 22 2109 19 22975805 PMC3483540
  154. [159]Ehrich M Field JK Liloglou T Xinarianos G Oeth P Nelson MR Cantor CR van den Boom D Cytosine methylation profiles as a molecular marker in non-small cell lung cancer Cancer Res 2006 66 10911 18 17108128
  155. [160]Brynczka C Labhart P Merrick BA NGF-mediated transcriptional targets of p53 in PC12 neuronal differentiation BMC Genomics 2007 8 139 17540029 PMC1894799
  156. [161]Anglim PP Alonzo TA Laird-Offringa IA DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update Mol Cancer 2008 7 81 18947422 PMC2585582
  157. [162]Consortium EP ENCODE Project Consortium An integrated encyclopedia of DNA elements in the human genome Nature 2012 489 57 74 22955616 PMC3439153
  158. [163]Chang S Wang RH Akagi K Kim KA Martin BK Cavallone L Haines DC Basik M Mai P Poggi E Isaacs C Looi LM Mun KS Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155 Nat Med 2011 17 1275 82 21946536 PMC3501198
  159. [164]Stracquadanio G Wang X Wallace MD Grawenda AM Zhang P Hewitt J Zeron-Medina J Castro-Giner F Tomlinson IP Goding CR Cygan KJ Fairbrother WG Thomas LF The importance of p53 pathway genetics in inherited and somatic cancer genomes Nat Rev Cancer 2016 16 251 65 27009395 PMC6854702
  160. [167]Brouwer A De Laere B Peeters D Peeters M Salgado R Dirix L Van Laere S Evaluation and consequences of heterogeneity in the circulating tumor cell compartment Oncotarget 2016 7 48625 43 10.18632/oncotarget.8015 26980749 PMC5217044 · DOI
  161. [168]Gerlinger M Rowan AJ Horswell S Larkin J Endesfelder D Gronroos E Martinez P Matthews N Stewart A Tarpey P Varela I Phillimore B Begum S Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N Engl J Med 2012 366 883 92 22397650 PMC4878653
  162. [169]Navin N Kendall J Troge J Andrews P Rodgers L McIndoo J Cook K Stepansky A Levy D Esposito D Muthuswamy L Krasnitz A McCombie WR Tumour evolution inferred by single-cell sequencing Nature 2011 472 90 94 21399628 PMC4504184
  163. [170]Kim KT Lee HW Lee HO Song HJ Jeong E Shin S Kim H Shin Y Nam DH Jeong BC Kirsch DG Joo KM Park WY Application of single-cell RNA sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell carcinoma Genome Biol 2016 17 80 27139883 PMC4852434

Cited by

Sorted by citations

Authors
Rajendran, B. K., & Deng, C.-X.
Affiliations
University of Macau (MO)
Corresponding author
Deng, Chu-Xia
ORCID
Venue
Oncotarget
Publisher
Impact Journals, LLC
Published
2017-04-19
Volume
8
Issue
30
Pages
50252-50272
ISSN
1949-2553 (ISSN-L)
DOI
10.18632/oncotarget.17225
PMC
PMC5564847
OpenAlex
W2607450268
Cited by
73
References
7
Citations by year
2026: 3 · 2025: 3 · 2024: 9 · 2023: 19 · 2022: 6 · 2021: 11 · 2020: 6 · 2019: 5 · 2018: 9 · 2017: 1 · 2016: 1
FWCI
0.58
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Oncotarget (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Universidade de Macau (FDCT 094/2015/A3)
  • Fundo para o Desenvolvimento das Ciências e da Tecnologia (094/2015/A3)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords
breast cancer, driver mutations, driver genes, mutation frequency, gene regulatory networks, signaling pathways, tumor initiation, tumor progression, metastasis
MeSH terms
Breast Neoplasms, Female, Humans, Mutation, Computational Biology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review